The company manufactures and sells new tires for two-wheelers, three-wheelers, and agricultural vehicles, while also producing precured tread rubber and bonding gum used in the tire retreading process.
The company lacks a durable moat, as evidenced by low net margins and a significant disconnect between volume growth and revenue. While they claim a brand advantage in the retreading niche, the business is highly sensitive to raw material price volatility and regulatory shifts in GST, indicating a lack of pricing power.
Capital has been primarily used to deleverage the balance sheet following the IPO and to fund a massive buildup in working capital. The negative cash conversion and high inventory levels suggest inefficient use of capital that has not yet translated into consistent shareholder returns.
The investment collapsed as the massive buildup in working capital proved to be a permanent trap rather than a temporary hurdle. The negative cash conversion cycle worsened, forcing the company to take on expensive debt to fund inventory that sat for over five months, while receivables from related parties became uncollectible. As raw material costs spiked, the company's lack of pricing power led to margin compression that wiped out the meager 4.8% net profit, leaving shareholders with a capital-intensive business that destroys value with every incremental sale.
RichFakir rates Tolins Tyres Ltd's business quality as poor — 38/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Tolins Tyres Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Tolins Tyres Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Tolins Tyres Ltd's fair value is about ₹27 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →